The message that Ainnova's CEO, Vinicio Vargas, continues to convey to audiences around the world is that this accessible, fast, and scalable solution is designed to support early intervention and ...

The message that Ainnova’s CEO, Vinicio Vargas, continues to convey to audiences around the world is that this accessible, fast, and scalable solution is designed to support early intervention and ...

There’s room on the market for new TAVI valves as long as they can compete with the best in practice, a researcher says.

Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of measuring the ...

Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions against an 'irrational' rush to move to younger patients ahead of the data.

Medtronic, Abbott and Boston Scientific had updates on their devices used in heart valve disease treatment at the event.

Medtronic plc, a global leader in healthcare technology, announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut transcatheter aortic ...

Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut transcatheter aortic valve replacement (TAVR) system in low-risk aortic stenosis ...

On Sunday, Medtronic published five-year data from a low-risk clinical trial of its Evolut transcatheter aortic valve replacement (TAVR) system. In the trial, TAVR, which assists patients ...